Safety and Immunogenicity of an Intramuscular H5N1 Inactivated, Split Virion Influenza Vaccine Adjuvanted with AF03 in Adults and Elderly subjects

Trial Profile

Safety and Immunogenicity of an Intramuscular H5N1 Inactivated, Split Virion Influenza Vaccine Adjuvanted with AF03 in Adults and Elderly subjects

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs AF03; Influenza A virus vaccine-H5N1
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 04 Nov 2014 This trial is recruiting in France, but is discontinued in the United Kingdom and completed in Belgium.
    • 08 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top